Expedition Therapeutics Secures $115 Million in Latest Series B Funding Round

Expedition Therapeutics secured $115 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Expedition Therapeutics Raises $115 million in Funding

NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B. This is a paid press release.

Investors Behind the Funding

The round was backed by the trading floor. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Expedition Therapeutics operates in Healthcare & Life Sciences. Expedition Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Use the funds for advancing its treatments and expanding its clinical trials.

Looking Ahead

NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B

Source reference: original announcement/article.